Jazz Pharma Ruling Clears US Roadblock for Rival Narcolepsy Drug

A US appeals court ordered Jazz Pharmaceuticals on Friday to de-list a patent related to its blockbuster narcolepsy drug Xyrem from the FDA's register of approved medications, in a win for rival drugmaker Avadel CNS Pharmaceuticals.
Reuters Health Information

source https://www.medscape.com/viewarticle/988755?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

DC’s Harllee Harper Is Using Public Health Tools to Prevent Gun Violence. Will It Work?